Skip to main content

Table 14 P values for change in NO levels within the groups (from baseline to the end of the treatment period) and between the groups

From: A randomized, double-blind, positive-controlled, prospective, dose-response clinical study to evaluate the efficacy and tolerability of an aqueous extract of Terminalia bellerica in lowering uric acid and creatinine levels in chronic kidney disease subjects with hyperuricemia

Group

4 weeks

12 weeks

24 weeks

A

p ≤ 0.0001

p ≤ 0.0001

p ≤ 0.0001

B

p ≤ 0.0001

p ≤ 0.0001

p ≤ 0.0001

C

p ≤ 0.0001

p ≤ 0.0001

p ≤ 0.0001

A vs B

ns

p ≤ 0.01

p ≤ 0.001

A vs C

ns

ns

ns

C vs B

ns

p ≤ 0.01

p ≤ 0.01